Posted by Michael Wonder on 27 Apr 2021
EMA grants accelerated assessment procedure for Nefecon for the treatment of IgA nephropathy
23 April 2021 - Calliditas Therapeutics today announced that its lead product candidate Nefecon, a novel oral formulation targeting down regulation of IgA1 for the treatment of primary IgA nephropathy, has been granted accelerated assessment procedure by the EMA's CHMP.
Calliditas expects to submit an marketing authorisation application to the EMA in Q2 2021.
